ID

21848

Descrizione

Phase I Study of Aprotinin in Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00354900

collegamento

https://clinicaltrials.gov/show/NCT00354900

Keywords

versioni (1)
  1. 04/05/17 04/05/17 -
Caricato su

4 maggio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Metastatic Breast Cancer NCT00354900

Inglese

Eligibility Metastatic Breast Cancer NCT00354900

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with a histologically or cytologically proven metastatic breast cancer.
Descrizione

Secondary malignant neoplasm of female breast

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0346993
patients with at least one bidimensionally measurable lesion (diameter > 1 cm), or an evaluable bone lesion that will not undergo biopsy.
Descrizione

Measurable Disease 2-Dimensional Quantity | Measurable Disease Diameter | Bone lesion Evaluable | Biopsy Absent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1705052
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C1301886
UMLS CUI [3,1]
C0238792
UMLS CUI [3,2]
C1516986
UMLS CUI [4,1]
C0005558
UMLS CUI [4,2]
C0332197
age > 18 years.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
life expectancy of at least 6 months.
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
ecog performance status 0-3.
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
screening laboratories within the following parameters: anc > 1500 cells/mm3, platelets > 100,000 cells/mm3, ast < 2 x upper limit of normal, bilirubin < 1.5 x upper limit of normal, calculated creatinine clearance > 30 cc/min by the cockroft and gault equation.
Descrizione

Laboratory Results | Absolute neutrophil count | Platelet Count measurement | Aspartate aminotransferase measurement | Serum total bilirubin measurement | Estimation of creatinine clearance by Cockcroft-Gault formula

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1254595
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0201899
UMLS CUI [5]
C1278039
UMLS CUI [6]
C2711451
concurrent treatment with hormonal therapy or trastuzumab is allowed.
Descrizione

Hormone Therapy | trastuzumab

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2]
C0728747
patients must be post-menopausal (either as a result of surgery, or amenorrhea for at least 12 consecutive months), or they must be practicing either abstinence, an adequate method of contraception (intrauterine device or barrier contraception), or their sexual partner must be sterile. women who are pregnant, breast-feeding, or who are fertile and not practicing an adequate means of contraception will be excluded.
Descrizione

Postmenopausal Due to Operative Surgical Procedures | Amenorrhea Duration | Sexual Abstinence | Contraceptive methods | Intrauterine Devices | Contraception, Barrier | Sexual Partner Infertility | Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Lacking

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0232970
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0543467
UMLS CUI [2,1]
C0002453
UMLS CUI [2,2]
C0449238
UMLS CUI [3]
C0036899
UMLS CUI [4]
C0700589
UMLS CUI [5]
C0021900
UMLS CUI [6]
C0004764
UMLS CUI [7,1]
C0036911
UMLS CUI [7,2]
C0021359
UMLS CUI [8]
C0032961
UMLS CUI [9]
C0006147
UMLS CUI [10,1]
C3831118
UMLS CUI [10,2]
C0700589
UMLS CUI [10,3]
C0332268
patients must have a central venous catheter.
Descrizione

Central venous catheter

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1145640
patients must be able to give informed consent indicating that they are aware of the investigational nature of this study.
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
no known cns metastases.
Descrizione

CNS metastases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0686377
no treatment with cytotoxic chemotherapy allowed within 21 days of treatment with aprotinin.
Descrizione

Cytotoxic Chemotherapy | Aprotinin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0677881
UMLS CUI [2]
C0003641
no treatment with investigational agents allowed within 21 days of treatment with aprotinin.
Descrizione

Investigational New Drugs | Aprotinin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C0003641
no severe cardiovascular disease including unstable heart rhythm, uncompensated congestive heart failure, unstable angina or myocardial infarction within 6 months.
Descrizione

Cardiovascular Disease Severe | Cardiac Arrhythmia | Congestive heart failure Uncompensated | Angina, Unstable | Myocardial Infarction

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0003811
UMLS CUI [3,1]
C0018802
UMLS CUI [3,2]
C0205433
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0027051
no bleeding diathesis or coagulopathy including concomitant use of anticoagulants for thromboembolic disease
Descrizione

Bleeding tendency | Blood Coagulation Disorders | Anticoagulants Thromboembolism

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2]
C0005779
UMLS CUI [3,1]
C0003280
UMLS CUI [3,2]
C0040038
no active anticoagulant therapy (including antiplatelet agents) for at least ten days.
Descrizione

Anticoagulant therapy | Antiplatelet Agents

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0150457
UMLS CUI [2]
C0085826
no active, uncontrolled bacterial, viral or fungal infection.
Descrizione

Bacterial Infection Uncontrolled | Virus Disease Uncontrolled | Mycoses Uncontrolled

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0004623
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0042769
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0026946
UMLS CUI [3,2]
C0205318
no patients who are known or expected to be allergic to aprotinin, or who have received prior aprotinin.
Descrizione

Aprotinin allergy | Aprotinin allergy Expected | Aprotinin Received

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0571793
UMLS CUI [2,1]
C0571793
UMLS CUI [2,2]
C1517001
UMLS CUI [3,1]
C0003641
UMLS CUI [3,2]
C1514756
no patient with chronic systolic blood pressure (sbp) < 90 mm hg. if the (sbp) is < 90 mm hg on the day of treatment intravenous fluid may be administered to restore intravascular volume, if clinically indicated. in such case, if iv fluid corrects the sbp then the study drug may be given
Descrizione

Systolic Pressure chronic | Administration of intravenous fluids | Volume Intravascular Restore | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0871470
UMLS CUI [1,2]
C0205191
UMLS CUI [2]
C0522792
UMLS CUI [3,1]
C0005850
UMLS CUI [3,2]
C0442123
UMLS CUI [3,3]
C1283255
UMLS CUI [4]
C0013230
Ritorna all'inizio della pagina

Similar models

Eligibility Metastatic Breast Cancer NCT00354900

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of female breast
Item
patients with a histologically or cytologically proven metastatic breast cancer.
boolean
C0346993 (UMLS CUI [1])
Measurable Disease 2-Dimensional Quantity | Measurable Disease Diameter | Bone lesion Evaluable | Biopsy Absent
Item
patients with at least one bidimensionally measurable lesion (diameter > 1 cm), or an evaluable bone lesion that will not undergo biopsy.
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1513041 (UMLS CUI [2,1])
C1301886 (UMLS CUI [2,2])
C0238792 (UMLS CUI [3,1])
C1516986 (UMLS CUI [3,2])
C0005558 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Age
Item
age > 18 years.
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 6 months.
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-3.
boolean
C1520224 (UMLS CUI [1])
Laboratory Results | Absolute neutrophil count | Platelet Count measurement | Aspartate aminotransferase measurement | Serum total bilirubin measurement | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
screening laboratories within the following parameters: anc > 1500 cells/mm3, platelets > 100,000 cells/mm3, ast < 2 x upper limit of normal, bilirubin < 1.5 x upper limit of normal, calculated creatinine clearance > 30 cc/min by the cockroft and gault equation.
boolean
C1254595 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C1278039 (UMLS CUI [5])
C2711451 (UMLS CUI [6])
Hormone Therapy | trastuzumab
Item
concurrent treatment with hormonal therapy or trastuzumab is allowed.
boolean
C0279025 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
Postmenopausal Due to Operative Surgical Procedures | Amenorrhea Duration | Sexual Abstinence | Contraceptive methods | Intrauterine Devices | Contraception, Barrier | Sexual Partner Infertility | Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Lacking
Item
patients must be post-menopausal (either as a result of surgery, or amenorrhea for at least 12 consecutive months), or they must be practicing either abstinence, an adequate method of contraception (intrauterine device or barrier contraception), or their sexual partner must be sterile. women who are pregnant, breast-feeding, or who are fertile and not practicing an adequate means of contraception will be excluded.
boolean
C0232970 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,3])
C0002453 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0036899 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
C0021900 (UMLS CUI [5])
C0004764 (UMLS CUI [6])
C0036911 (UMLS CUI [7,1])
C0021359 (UMLS CUI [7,2])
C0032961 (UMLS CUI [8])
C0006147 (UMLS CUI [9])
C3831118 (UMLS CUI [10,1])
C0700589 (UMLS CUI [10,2])
C0332268 (UMLS CUI [10,3])
Central venous catheter
Item
patients must have a central venous catheter.
boolean
C1145640 (UMLS CUI [1])
Informed Consent
Item
patients must be able to give informed consent indicating that they are aware of the investigational nature of this study.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CNS metastases
Item
no known cns metastases.
boolean
C0686377 (UMLS CUI [1])
Cytotoxic Chemotherapy | Aprotinin
Item
no treatment with cytotoxic chemotherapy allowed within 21 days of treatment with aprotinin.
boolean
C0677881 (UMLS CUI [1])
C0003641 (UMLS CUI [2])
Investigational New Drugs | Aprotinin
Item
no treatment with investigational agents allowed within 21 days of treatment with aprotinin.
boolean
C0013230 (UMLS CUI [1])
C0003641 (UMLS CUI [2])
Cardiovascular Disease Severe | Cardiac Arrhythmia | Congestive heart failure Uncompensated | Angina, Unstable | Myocardial Infarction
Item
no severe cardiovascular disease including unstable heart rhythm, uncompensated congestive heart failure, unstable angina or myocardial infarction within 6 months.
boolean
C0007222 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0003811 (UMLS CUI [2])
C0018802 (UMLS CUI [3,1])
C0205433 (UMLS CUI [3,2])
C0002965 (UMLS CUI [4])
C0027051 (UMLS CUI [5])
Bleeding tendency | Blood Coagulation Disorders | Anticoagulants Thromboembolism
Item
no bleeding diathesis or coagulopathy including concomitant use of anticoagulants for thromboembolic disease
boolean
C1458140 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
C0003280 (UMLS CUI [3,1])
C0040038 (UMLS CUI [3,2])
Anticoagulant therapy | Antiplatelet Agents
Item
no active anticoagulant therapy (including antiplatelet agents) for at least ten days.
boolean
C0150457 (UMLS CUI [1])
C0085826 (UMLS CUI [2])
Bacterial Infection Uncontrolled | Virus Disease Uncontrolled | Mycoses Uncontrolled
Item
no active, uncontrolled bacterial, viral or fungal infection.
boolean
C0004623 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0042769 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0026946 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
Aprotinin allergy | Aprotinin allergy Expected | Aprotinin Received
Item
no patients who are known or expected to be allergic to aprotinin, or who have received prior aprotinin.
boolean
C0571793 (UMLS CUI [1])
C0571793 (UMLS CUI [2,1])
C1517001 (UMLS CUI [2,2])
C0003641 (UMLS CUI [3,1])
C1514756 (UMLS CUI [3,2])
Systolic Pressure chronic | Administration of intravenous fluids | Volume Intravascular Restore | Investigational New Drugs
Item
no patient with chronic systolic blood pressure (sbp) < 90 mm hg. if the (sbp) is < 90 mm hg on the day of treatment intravenous fluid may be administered to restore intravascular volume, if clinically indicated. in such case, if iv fluid corrects the sbp then the study drug may be given
boolean
C0871470 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0522792 (UMLS CUI [2])
C0005850 (UMLS CUI [3,1])
C0442123 (UMLS CUI [3,2])
C1283255 (UMLS CUI [3,3])
C0013230 (UMLS CUI [4])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial